US-based medical technology firm Medtronic has received CE Mark approval for its Resolute Onyx drug-eluting stent (DES).
Launched internationally, the Resolute Onyx DES was first implanted during the XII International Course of Endovascular and Myocardial Therapy in Madrid, Spain.
The company said that the Resolute Onyx DES is not approved in the US.
Hospital Universitario Clínico San Carlos interventional cardiologist Dr Eulogio Garcia said: "Following my experience with the Resolute Onyx DES, I have been able to see first-hand how the CoreWire technology offers improved deliverability in complex lesions, enhanced conformability to the vessel wall and greater radiopacity for more accurate stent placement."
Built on the clinical performance and deliverability of the Resolute Integrity DES, the Resolute Onyx DES features CoreWire technology allowing it a denser core metal wrapped in a cobalt alloy outer layer, and helps to increase radiopacity.
The Resolute Onyx DES’s thinner struts helps to improve deliverability without compromising radial and longitudinal strength.
Medtronic vice-president Jason Weidman said: "CoreWire technology is an exciting innovation that will have a measurable impact on clinical practice today and tomorrow.
"The advancements of the Resolute Onyx DES specifically address the need for continued procedural efficiency and ease-of-use. Importantly, and in contrast to some current DES technologies, it achieves meaningful deliverability enhancements with no compromise to stent strength."
The Resolute Onyx DES also includes a new delivery system with PowerTrac technology, which was launched earlier this year with the NC Euphora Noncompliant Balloon Dilatation Catheter.
The company said that CoreWire technology is the new DES advancement after Continuous Sinusoid technology (CST), which was previously launched with the Resolute Integrity DES and the Integrity bare-metal stent.